Meditech raises $2.2m in share purchase plan
Tuesday, 02 December, 2003
Meditech Research (ASX:MRL) has added AUD$2 million to its coffers through a shareholder purchase plan, bringing the total capital raised recently to $6.8 million.
"We've had a very satisfactory outcome -- we're very pleased with that," CEO Chris Carter said.
The capital will be used to continue the development of the company's HyACT technology for oncology applications, and a new antifungal treatment HyAPE, as well as to fund early stage development of novel carbohydrate therapeutics in collaboration with Griffith University's Institute for Glycomics.
Carter said the company was in advanced discussions with an international biotechnology company to enter into a collaboration and licensing agreement. "This potential collaboration should be good for Meditech," he said.
The deal is likely to be finalised before the end of the year, according to an earlier announcement made by the company.
Most of the patients for the first part of Meditech's HyCAMP Phase I clinical trial are now enrolled, and results are expected in early 2004.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
